NorwayNorway

Norway

05.03.2004

Oslo - Oslo-based Affitech AS, a human antibody discovery and develop-ment company, and the Norwegian Radium Hospital received in mid-February some Euro704,000 from FUGE (Norwegian national functional genomics program) to carry out research on the development of new cancer therapeutics, vaccines and diagnostics.

NorwayNorway

08.03.2012

With a bold approach, including next-generation DNA sequencing (NGS) and state-of-the-art biobanking systems, Norway is pushing forward personalised cancer treatments in its national health care system. Clinical-quality genome...

NorwayNorway

06.03.2012

Bionor Pharma ASA’s development of an HIV vaccine is back on track. In mid-February, the Oslo-based company announced positive results from a Phase IIb study. When combined with antiretroviral treatment, the Vacc-4x vaccine...

NorwayNorway

19.01.2012

Oslo – The north lights up with financial flares. Norwegian cancer specialist Clavis Pharma ASA has raised €21m through a placement of new shares. The 2.8 million shares represent approximately 9.4% of the current stock in the...

NorwayNorway

11.01.2012

Bergen – BerGenBio A/S announced it has completed an €6.9m Series A financing round. The money will be spent in taking their lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors are...

NorwayNorway

13.12.2011

Reykjavik – Iceland’s deCODE Genetics, which Arch Venture Partners and Polaris Venture Partners lifted out of bankruptcy in January 2010, has been making a comeback of late. In mid-October, the genome analyser announced it had...

NorwayNorway

01.10.2011

Oslo/Leverkusen – Norwegian radiotherapy specialist Algeta ASA and German drugmaker Bayer have presented new data on their cancer drug alpharadin. The radium-223-chloride pharmaceutical showed an increased overall survival rate...

NorwayNorway

30.09.2011

Lysaker/Osaka - Pronova Biopharma SA is set on entering the Japanese market with its TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia. Pronova's partner Takeda Pharmaceutical Company Limited submitted a...

NorwayNorway

14.06.2011

Laskut/Berlin – Researchers from Finland’s Technical Research Center VTT and the Charité Hospital in the German capital have come a step closer to a personalised diagnostic test for cancer. Matej Orešic (VTT) and Carsten Denkert...

NorwayNorway

12.06.2011

Oslo – Norwegian cancer drug development company Clavis Pharma ASA will receive a grant from the Norwegian government for the development of a companion diagnostic in acute myeloid leuk­aemia (AML). The Research Council of Norway...

NorwayNorway

17.05.2011

Oslo – Clavis Pharma ASA has signed a licensing deal with US firm Translational Therapeutics, Inc., for the development and commercialization of CP-4033, a patented Lipid Vector Technology (LVT) derivative of ribavirin under...

Displaying results 1 to 10 out of 92

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/article/norway-5.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.95 EUR2.33%
  • 4SC0.92 EUR2.22%
  • BIOTEST80.77 EUR1.62%

FLOP

  • CYTOS0.27 CHF-6.90%
  • CO.DON2.56 EUR-3.40%
  • WILEX2.10 EUR-2.78%

TOP

  • CYTOS0.27 CHF58.8%
  • EPIGENOMICS5.20 EUR36.8%
  • FORMYCON10.74 EUR36.1%

FLOP

  • 4SC0.92 EUR-13.2%
  • CO.DON2.56 EUR-12.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.00 CHF2321.1%
  • CO.DON2.56 EUR156.0%
  • BB BIOTECH185.30 EUR63.0%

FLOP

  • CYTOS0.27 CHF-91.9%
  • 4SC0.92 EUR-48.3%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014

Current issue

All issues